APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostate Specific Antigen

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Prostate Specific Antigen Market Outlook and Growth Opportunities 2026

19 December 2025192 pages

Choose your research edition.

Industry ResearchProstate Specific Antigen Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Specific Antigen Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Prostate Specific Antigen Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Specific Antigen Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Specific Antigen Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Prostate Specific Antigen market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Prostate Specific Antigen is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prostate Specific Antigen is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prostate Specific Antigen is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Prostate Specific Antigen market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Prostate Specific Antigen market include OncBioMune Pharmaceuticals Inc., Inovio Pharmaceuticals, Inc., GenSpera, Inc., Curevac AG, Bavarian Nordic A/S, Aeterna Zentaris Inc. and Advaxis, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Prostate Specific Antigen market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostate Specific Antigen and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostate Specific Antigen sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prostate Specific Antigen market size, projected growth trends, production technologies, key applications, and end-use industries.

Prostate Specific Antigen Segment by Company

OncBioMune Pharmaceuticals Inc.

Inovio Pharmaceuticals, Inc.

GenSpera, Inc.

Curevac AG

Bavarian Nordic A/S

Aeterna Zentaris Inc.

Advaxis, Inc.

Prostate Specific Antigen Segment by Type

INO-5150

G-115

AEZS-120

ADXS-PSA

Others

Prostate Specific Antigen Segment by Application

Prostate Cancer

Metastatic Hormone Refractory Prostate Cancer

Others

Prostate Specific Antigen Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Prostate Specific Antigen status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Prostate Specific Antigen market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prostate Specific Antigen significant trends, drivers, influence factors in global and regions.

6. To analyze Prostate Specific Antigen competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Specific Antigen market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Specific Antigen and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Specific Antigen.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Prostate Specific Antigen market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostate Specific Antigen industry.

Chapter 3: Detailed analysis of Prostate Specific Antigen manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Prostate Specific Antigen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Prostate Specific Antigen in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prostate Specific Antigen Industry Trends Table 2. Prostate Specific Antigen Industry Drivers Table 3. Prostate Specific Antigen Industry Opportunities and Challenges Table 4. Prostate Specific Antigen Industry Restraints Table 5. Global Prostate Specific Antigen Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prostate Specific Antigen Revenue Share by Company (2021-2026) Table 7. Global Prostate Specific Antigen Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Prostate Specific Antigen Sales Volume Share by Company (2021-2026) Table 9. Global Prostate Specific Antigen Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Prostate Specific Antigen Company Ranking, (2024-2026) & (USD Million) Table 11. Global Prostate Specific Antigen Key Company Manufacturing Base & Headquarters Table 12. Global Prostate Specific Antigen Company, Product Type & Application Table 13. Global Prostate Specific Antigen Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Prostate Specific Antigen by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of INO-5150 Table 18. Significant Companies of G-115 Table 19. Significant Companies of AEZS-120 Table 20. Significant Companies of ADXS-PSA Table 21. Significant Companies of Others Table 22. Global Prostate Specific Antigen Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Prostate Specific Antigen Sales Volume by Type (2021-2026) & (W Units) Table 24. Global Prostate Specific Antigen Sales Volume by Type (2027-2032) & (W Units) Table 25. Global Prostate Specific Antigen Sales Volume Share by Type (2021-2026) Table 26. Global Prostate Specific Antigen Sales Volume Share by Type (2027-2032) Table 27. Global Prostate Specific Antigen Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Prostate Specific Antigen Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Prostate Specific Antigen Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Prostate Specific Antigen Sales Value Share by Type (2021-2026) Table 31. Global Prostate Specific Antigen Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Prostate Cancer Table 33. Significant Companies of Metastatic Hormone Refractory Prostate Cancer Table 34. Significant Companies of Others Table 35. Global Prostate Specific Antigen Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Prostate Specific Antigen Sales Volume by Application (2021-2026) & (W Units) Table 37. Global Prostate Specific Antigen Sales Volume by Application (2027-2032) & (W Units) Table 38. Global Prostate Specific Antigen Sales Volume Share by Application (2021-2026) Table 39. Global Prostate Specific Antigen Sales Volume Share by Application (2027-2032) Table 40. Global Prostate Specific Antigen Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Prostate Specific Antigen Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Prostate Specific Antigen Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Prostate Specific Antigen Sales Value Share by Application (2021-2026) Table 44. Global Prostate Specific Antigen Sales Value Share by Application (2027-2032) Table 45. Global Prostate Specific Antigen Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Prostate Specific Antigen Sales by Region (2021-2026) & (W Units) Table 47. Global Prostate Specific Antigen Sales Market Share by Region (2021-2026) Table 48. Global Prostate Specific Antigen Sales by Region (2027-2032) & (W Units) Table 49. Global Prostate Specific Antigen Sales Market Share by Region (2027-2032) Table 50. Global Prostate Specific Antigen Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Prostate Specific Antigen Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Prostate Specific Antigen Sales Value Share by Region (2021-2026) Table 53. Global Prostate Specific Antigen Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Prostate Specific Antigen Sales Value Share by Region (2027-2032) Table 55. Global Prostate Specific Antigen Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Prostate Specific Antigen Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Prostate Specific Antigen Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Global Prostate Specific Antigen Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Prostate Specific Antigen Sales by Country (2021-2026) & (W Units) Table 60. Global Prostate Specific Antigen Sales Market Share by Country (2021-2026) Table 61. Global Prostate Specific Antigen Sales by Country (2027-2032) & (W Units) Table 62. Global Prostate Specific Antigen Sales Market Share by Country (2027-2032) Table 63. Global Prostate Specific Antigen Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Prostate Specific Antigen Sales Value Market Share by Country (2021-2026) Table 65. Global Prostate Specific Antigen Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Prostate Specific Antigen Sales Value Market Share by Country (2027-2032) Table 67. OncBioMune Pharmaceuticals Inc. Company Information Table 68. OncBioMune Pharmaceuticals Inc. Business Overview Table 69. OncBioMune Pharmaceuticals Inc. Prostate Specific Antigen Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. OncBioMune Pharmaceuticals Inc. Prostate Specific Antigen Product Portfolio Table 71. OncBioMune Pharmaceuticals Inc. Recent Development Table 72. Inovio Pharmaceuticals, Inc. Company Information Table 73. Inovio Pharmaceuticals, Inc. Business Overview Table 74. Inovio Pharmaceuticals, Inc. Prostate Specific Antigen Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Inovio Pharmaceuticals, Inc. Prostate Specific Antigen Product Portfolio Table 76. Inovio Pharmaceuticals, Inc. Recent Development Table 77. GenSpera, Inc. Company Information Table 78. GenSpera, Inc. Business Overview Table 79. GenSpera, Inc. Prostate Specific Antigen Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. GenSpera, Inc. Prostate Specific Antigen Product Portfolio Table 81. GenSpera, Inc. Recent Development Table 82. Curevac AG Company Information Table 83. Curevac AG Business Overview Table 84. Curevac AG Prostate Specific Antigen Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Curevac AG Prostate Specific Antigen Product Portfolio Table 86. Curevac AG Recent Development Table 87. Bavarian Nordic A/S Company Information Table 88. Bavarian Nordic A/S Business Overview Table 89. Bavarian Nordic A/S Prostate Specific Antigen Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Bavarian Nordic A/S Prostate Specific Antigen Product Portfolio Table 91. Bavarian Nordic A/S Recent Development Table 92. Aeterna Zentaris Inc. Company Information Table 93. Aeterna Zentaris Inc. Business Overview Table 94. Aeterna Zentaris Inc. Prostate Specific Antigen Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Aeterna Zentaris Inc. Prostate Specific Antigen Product Portfolio Table 96. Aeterna Zentaris Inc. Recent Development Table 97. Advaxis, Inc. Company Information Table 98. Advaxis, Inc. Business Overview Table 99. Advaxis, Inc. Prostate Specific Antigen Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Advaxis, Inc. Prostate Specific Antigen Product Portfolio Table 101. Advaxis, Inc. Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Prostate Specific Antigen Distributors List Table 105. Prostate Specific Antigen Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Prostate Specific Antigen Product Image Figure 2. Global Prostate Specific Antigen Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostate Specific Antigen Sales Value (2021-2032) & (US$ Million) Figure 4. Global Prostate Specific Antigen Sales (2021-2032) & (W Units) Figure 5. Global Prostate Specific Antigen Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Prostate Specific Antigen Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. INO-5150 Image Figure 10. G-115 Image Figure 11. AEZS-120 Image Figure 12. ADXS-PSA Image Figure 13. Others Image Figure 14. Global Prostate Specific Antigen Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Prostate Specific Antigen Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Prostate Specific Antigen Sales Volume Share by Type (2021-2032) Figure 17. Global Prostate Specific Antigen Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Prostate Specific Antigen Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Prostate Specific Antigen Sales Value Share by Type (2021-2032) Figure 20. Prostate Cancer Image Figure 21. Metastatic Hormone Refractory Prostate Cancer Image Figure 22. Others Image Figure 23. Global Prostate Specific Antigen Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Prostate Specific Antigen Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Prostate Specific Antigen Sales Volume Share by Application (2021-2032) Figure 26. Global Prostate Specific Antigen Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Prostate Specific Antigen Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Prostate Specific Antigen Sales Value Share by Application (2021-2032) Figure 29. Global Prostate Specific Antigen Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 30. Global Prostate Specific Antigen Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Prostate Specific Antigen Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Prostate Specific Antigen Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Prostate Specific Antigen Sales Value (2021-2032) & (US$ Million) Figure 34. North America Prostate Specific Antigen Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Prostate Specific Antigen Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Prostate Specific Antigen Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Prostate Specific Antigen Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Prostate Specific Antigen Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Prostate Specific Antigen Sales Value (2021-2032) & (US$ Million) Figure 40. South America Prostate Specific Antigen Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Prostate Specific Antigen Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Prostate Specific Antigen Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Prostate Specific Antigen Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Prostate Specific Antigen Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Prostate Specific Antigen Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • INO-5150
  • G-115
  • AEZS-120
  • ADXS-PSA
  • Others
Applications
  • Prostate Cancer
  • Metastatic Hormone Refractory Prostate Cancer
  • Others
Companies covered
  • OncBioMune Pharmaceuticals Inc.
  • Inovio Pharmaceuticals, Inc.
  • GenSpera, Inc.
  • Curevac AG
  • Bavarian Nordic A/S
  • Aeterna Zentaris Inc.
  • Advaxis, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prostate Specific Antigen Sales Value (2021-2032)
  4. 1.2.2 Global Prostate Specific Antigen Sales Volume (2021-2032)
  5. 1.2.3 Global Prostate Specific Antigen Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Prostate Specific Antigen Market Dynamics
  1. 2.1 Prostate Specific Antigen Industry Trends
  2. 2.2 Prostate Specific Antigen Industry Drivers
  3. 2.3 Prostate Specific Antigen Industry Opportunities and Challenges
  4. 2.4 Prostate Specific Antigen Industry Restraints
3 Prostate Specific Antigen Market by Company
  1. 3.1 Global Prostate Specific Antigen Company Revenue Ranking in 2025
  2. 3.2 Global Prostate Specific Antigen Revenue by Company (2021-2026)
  3. 3.3 Global Prostate Specific Antigen Sales Volume by Company (2021-2026)
  4. 3.4 Global Prostate Specific Antigen Average Price by Company (2021-2026)
  5. 3.5 Global Prostate Specific Antigen Company Ranking (2024-2026)
  6. 3.6 Global Prostate Specific Antigen Company Manufacturing Base and Headquarters
  7. 3.7 Global Prostate Specific Antigen Company Product Type and Application
  8. 3.8 Global Prostate Specific Antigen Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Prostate Specific Antigen Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Prostate Specific Antigen Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Prostate Specific Antigen Market by Type
  1. 4.1 Prostate Specific Antigen Type Introduction
  2. 4.1.1 INO-5150
  3. 4.1.2 G-115
  4. 4.1.3 AEZS-120
  5. 4.1.4 ADXS-PSA
  6. 4.1.5 Others
  7. 4.2 Global Prostate Specific Antigen Sales Volume by Type
  8. 4.2.1 Global Prostate Specific Antigen Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Prostate Specific Antigen Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Prostate Specific Antigen Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Prostate Specific Antigen Sales Value by Type
  12. 4.3.1 Global Prostate Specific Antigen Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Prostate Specific Antigen Sales Value by Type (2021-2032)
  14. 4.3.3 Global Prostate Specific Antigen Sales Value Share by Type (2021-2032)
5 Prostate Specific Antigen Market by Application
  1. 5.1 Prostate Specific Antigen Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Metastatic Hormone Refractory Prostate Cancer
  4. 5.1.3 Others
  5. 5.2 Global Prostate Specific Antigen Sales Volume by Application
  6. 5.2.1 Global Prostate Specific Antigen Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Prostate Specific Antigen Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Prostate Specific Antigen Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Prostate Specific Antigen Sales Value by Application
  10. 5.3.1 Global Prostate Specific Antigen Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Prostate Specific Antigen Sales Value by Application (2021-2032)
  12. 5.3.3 Global Prostate Specific Antigen Sales Value Share by Application (2021-2032)
6 Prostate Specific Antigen Regional Sales and Value Analysis
  1. 6.1 Global Prostate Specific Antigen Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prostate Specific Antigen Sales by Region (2021-2032)
  3. 6.2.1 Global Prostate Specific Antigen Sales by Region: 2021-2026
  4. 6.2.2 Global Prostate Specific Antigen Sales by Region (2027-2032)
  5. 6.3 Global Prostate Specific Antigen Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Prostate Specific Antigen Sales Value by Region (2021-2032)
  7. 6.4.1 Global Prostate Specific Antigen Sales Value by Region: 2021-2026
  8. 6.4.2 Global Prostate Specific Antigen Sales Value by Region (2027-2032)
  9. 6.5 Global Prostate Specific Antigen Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Prostate Specific Antigen Sales Value (2021-2032)
  12. 6.6.2 North America Prostate Specific Antigen Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Prostate Specific Antigen Sales Value (2021-2032)
  15. 6.7.2 Europe Prostate Specific Antigen Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Prostate Specific Antigen Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Prostate Specific Antigen Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Prostate Specific Antigen Sales Value (2021-2032)
  21. 6.9.2 South America Prostate Specific Antigen Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Prostate Specific Antigen Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Prostate Specific Antigen Sales Value Share by Country, 2025 VS 2032
7 Prostate Specific Antigen Country-level Sales and Value Analysis
  1. 7.1 Global Prostate Specific Antigen Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prostate Specific Antigen Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Prostate Specific Antigen Sales by Country (2021-2032)
  4. 7.3.1 Global Prostate Specific Antigen Sales by Country (2021-2026)
  5. 7.3.2 Global Prostate Specific Antigen Sales by Country (2027-2032)
  6. 7.4 Global Prostate Specific Antigen Sales Value by Country (2021-2032)
  7. 7.4.1 Global Prostate Specific Antigen Sales Value by Country (2021-2026)
  8. 7.4.2 Global Prostate Specific Antigen Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Prostate Specific Antigen Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Prostate Specific Antigen Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Prostate Specific Antigen Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 OncBioMune Pharmaceuticals Inc.
  2. 8.1.1 OncBioMune Pharmaceuticals Inc. Company Information
  3. 8.1.2 OncBioMune Pharmaceuticals Inc. Business Overview
  4. 8.1.3 OncBioMune Pharmaceuticals Inc. Prostate Specific Antigen Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 OncBioMune Pharmaceuticals Inc. Prostate Specific Antigen Product Portfolio
  6. 8.1.5 OncBioMune Pharmaceuticals Inc. Recent Developments
  7. 8.2 Inovio Pharmaceuticals, Inc.
  8. 8.2.1 Inovio Pharmaceuticals, Inc. Company Information
  9. 8.2.2 Inovio Pharmaceuticals, Inc. Business Overview
  10. 8.2.3 Inovio Pharmaceuticals, Inc. Prostate Specific Antigen Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Inovio Pharmaceuticals, Inc. Prostate Specific Antigen Product Portfolio
  12. 8.2.5 Inovio Pharmaceuticals, Inc. Recent Developments
  13. 8.3 GenSpera, Inc.
  14. 8.3.1 GenSpera, Inc. Company Information
  15. 8.3.2 GenSpera, Inc. Business Overview
  16. 8.3.3 GenSpera, Inc. Prostate Specific Antigen Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GenSpera, Inc. Prostate Specific Antigen Product Portfolio
  18. 8.3.5 GenSpera, Inc. Recent Developments
  19. 8.4 Curevac AG
  20. 8.4.1 Curevac AG Company Information
  21. 8.4.2 Curevac AG Business Overview
  22. 8.4.3 Curevac AG Prostate Specific Antigen Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Curevac AG Prostate Specific Antigen Product Portfolio
  24. 8.4.5 Curevac AG Recent Developments
  25. 8.5 Bavarian Nordic A/S
  26. 8.5.1 Bavarian Nordic A/S Company Information
  27. 8.5.2 Bavarian Nordic A/S Business Overview
  28. 8.5.3 Bavarian Nordic A/S Prostate Specific Antigen Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bavarian Nordic A/S Prostate Specific Antigen Product Portfolio
  30. 8.5.5 Bavarian Nordic A/S Recent Developments
  31. 8.6 Aeterna Zentaris Inc.
  32. 8.6.1 Aeterna Zentaris Inc. Company Information
  33. 8.6.2 Aeterna Zentaris Inc. Business Overview
  34. 8.6.3 Aeterna Zentaris Inc. Prostate Specific Antigen Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Aeterna Zentaris Inc. Prostate Specific Antigen Product Portfolio
  36. 8.6.5 Aeterna Zentaris Inc. Recent Developments
  37. 8.7 Advaxis, Inc.
  38. 8.7.1 Advaxis, Inc. Company Information
  39. 8.7.2 Advaxis, Inc. Business Overview
  40. 8.7.3 Advaxis, Inc. Prostate Specific Antigen Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Advaxis, Inc. Prostate Specific Antigen Product Portfolio
  42. 8.7.5 Advaxis, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Prostate Specific Antigen Value Chain Analysis
  2. 9.1.1 Prostate Specific Antigen Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Prostate Specific Antigen Sales Mode & Process
  6. 9.2 Prostate Specific Antigen Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Prostate Specific Antigen Distributors
  9. 9.2.3 Prostate Specific Antigen Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst